Chinese vaccine manufacturer joins AstraZeneca’s global Covid-19 vaccine program
A Shenzhen-based Chinese vaccine maker has agreed to help manufacture AstraZeneca’s Covid-19 vaccine for China if it is approved by local regulators.
KangTai Biological Products, or BioKangtai, has partnered with the British drug developer to produce and commercialize its vaccine candidate AZD1222, originally developed by the University of Oxford. China is AstraZeneca’s second biggest market and contributes approximately one-fifth of its total revenue.
BioKangtai will manufacture at least 100 million doses of the vaccine by the end of this year and at least 200 million doses by the end of 2021, the statement said.
In June, AstraZeneca committed to producing 2 billion doses of its experimental Covid-19 vaccine. The company has struck deals to supply its vaccine in Europe and the U.S., and has partnered with the Serum Institute of India to provide 1 billion doses for low- and middle-income countries. Japan will also purchase 120 million doses from AstraZeneca, starting with 30 million doses by March next year, Reuters reported.
KangTai Biological Products, or BioKangtai, has partnered with the British drug developer to produce and commercialize its vaccine candidate AZD1222, originally developed by the University of Oxford. China is AstraZeneca’s second biggest market and contributes approximately one-fifth of its total revenue.
BioKangtai will manufacture at least 100 million doses of the vaccine by the end of this year and at least 200 million doses by the end of 2021, the statement said.
In June, AstraZeneca committed to producing 2 billion doses of its experimental Covid-19 vaccine. The company has struck deals to supply its vaccine in Europe and the U.S., and has partnered with the Serum Institute of India to provide 1 billion doses for low- and middle-income countries. Japan will also purchase 120 million doses from AstraZeneca, starting with 30 million doses by March next year, Reuters reported.
.png)
No hay comentarios:
Publicar un comentario